Valuation: Recursion Pharmaceuticals, Inc.

Market Cap 2.24B 2.02B 1.86B 1.68B 3.19B 210B 3.27B 22.33B 8.9B 112B 8.4B 8.22B 358B P/E 2026 *
-4.04x
P/E 2027 * -4.23x
Enterprise Value 1.68B 1.51B 1.4B 1.26B 2.39B 158B 2.45B 16.77B 6.68B 84.4B 6.31B 6.17B 269B EV / Sales 2026 *
41.7x
EV / Sales 2027 * 43.2x
Free-Float
98.26%
Yield 2026 *
-
Yield 2027 * -
1 day+1.13%
1 week-7.47%
Current month-10.92%
1 month-17.66%
3 months+7.16%
6 months+10.12%
Current year-12.22%
1 week 3.47
Extreme 3.47
3.87
1 month 3.42
Extreme 3.42
4.52
Current year 2.77
Extreme 2.77
5.24
1 year 2.77
Extreme 2.77
5.24
3 years 2.77
Extreme 2.77
15.74
5 years 2.77
Extreme 2.77
21.19
10 years 2.77
Extreme 2.77
42.81
Manager TitleAgeSince
Chief Executive Officer 43 01/01/2026
Director of Finance/CFO 48 20/11/2024
Chief Tech/Sci/R&D Officer 57 06/04/2026
Director TitleAgeSince
Director/Board Member 44 04/11/2013
Director/Board Member 62 04/11/2013
Director/Board Member 37 01/09/2016
Date Insider Type Main position Quantity % Market Cap. Importance
3/11/26 Sell

Founder

-40,000 0.0067%
2/11/26 Free

Chairman

156,658 0.0262%
6/10/26 Sell

Founder

-50,000 0.0093%
Change 5-day change 1-year change 3-year change Capi.($)
+1.13%-7.47%-23.78%-34.25% 2.21B
-1.06%-0.07%+60.76%+68.61% 68.32B
+1.30%+7.41%+14.79%+92.69% 60.26B
+0.39%+0.30%+20.04%+98.33% 55.86B
-0.95%+11.17%+22.21%+110.93% 48.43B
-0.23%+4.07%+25.63%+40.08% 45.34B
-6.40%-9.51%+181.99%+816.79% 41.76B
+1.97%+3.50%+25.78%+50.98% 34.5B
-0.56%-0.48%+85.57%+65.40% 33.8B
+1.05%+9.77%-37.66%+408.42% 26.21B
Average -0.34%+0.56%+37.53%+171.80% 42B
Weighted average by Cap. -0.52%+1.40%+44.97%+171.97%

Financials

2026 *2027 *
Net sales 40.32M 36.34M 33.57M 30.35M 57.42M 3.78B 58.84M 402M 160M 2.03B 151M 148M 6.45B 44.2M 39.84M 36.81M 33.27M 62.95M 4.15B 64.5M 441M 176M 2.22B 166M 162M 7.07B
Net income -479M -431M -399M -360M -682M -44.9B -699M -4.78B -1.9B -24.05B -1.8B -1.76B -76.52B -494M -446M -412M -372M -704M -46.36B -721M -4.93B -1.97B -24.83B -1.86B -1.82B -79.02B
Net Debt -558M -503M -464M -420M -794M -52.3B -814M -5.56B -2.22B -28.01B -2.09B -2.05B -89.14B -326M -294M -272M -246M -465M -30.6B -476M -3.26B -1.3B -16.39B -1.22B -1.2B -52.16B
Projected Income Statement - Annual - Recursion Pharmaceuticals, Inc.
Logo Recursion Pharmaceuticals, Inc.
Recursion Pharmaceuticals, Inc. is a clinical-stage TechBio company decoding biology and chemistry to industrialize drug discovery. Its Recursion Operating System (OS), a platform built across diverse technologies, enables the Company to map and navigate trillions of biological and chemical relationships within the Recursion Data Universe. The Company integrates physical and digital components as iterative loops of atoms and bits, scaling wet lab biology and chemistry data organized into virtuous cycles with computational tools to rapidly translate silico hypotheses into validated insights and novel chemistry. Its clinical programs in oncology and rare diseases include REC-617, REC-1245, REC-3565 and REC-4539. Its REC-617 is an orally bioavailable, cyclin-dependent kinase 7 (CDK7) inhibitor for the treatment of advanced solid tumors. Its REV102 program targets ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1), an enzyme implicated in the pathogenesis of HPP.
Employees
600
Date Price Change Volume
11/11/26 USD 3.590 +1.13% 16,559,251
10/11/26 USD 3.550 -6.70% 19,099,840
09/11/26 USD 3.805 +8.10% 20,366,666
06/11/26 USD 3.520 +0.57% 15,585,949
05/11/26 USD 3.500 -9.79% 25,416,509
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
MarketScreener Ratings - Recursion Pharmaceuticals, Inc.
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
7
Last Close Price
3.590USD
Average target price
7.317USD
Spread / Average Target
+103.81%
  1. Stock Market
  2. Stocks
  3. RXRX Stock